Correlation Between Ameriprise Financial and Mineralys Therapeutics,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Ameriprise Financial and Mineralys Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Ameriprise Financial and Mineralys Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Ameriprise Financial and Mineralys Therapeutics, Common, you can compare the effects of market volatilities on Ameriprise Financial and Mineralys Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Ameriprise Financial with a short position of Mineralys Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Ameriprise Financial and Mineralys Therapeutics,.

Diversification Opportunities for Ameriprise Financial and Mineralys Therapeutics,

0.19
  Correlation Coefficient

Average diversification

The 3 months correlation between Ameriprise and Mineralys is 0.19. Overlapping area represents the amount of risk that can be diversified away by holding Ameriprise Financial and Mineralys Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mineralys Therapeutics, and Ameriprise Financial is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Ameriprise Financial are associated (or correlated) with Mineralys Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mineralys Therapeutics, has no effect on the direction of Ameriprise Financial i.e., Ameriprise Financial and Mineralys Therapeutics, go up and down completely randomly.

Pair Corralation between Ameriprise Financial and Mineralys Therapeutics,

Considering the 90-day investment horizon Ameriprise Financial is expected to generate 0.42 times more return on investment than Mineralys Therapeutics,. However, Ameriprise Financial is 2.37 times less risky than Mineralys Therapeutics,. It trades about 0.16 of its potential returns per unit of risk. Mineralys Therapeutics, Common is currently generating about 0.03 per unit of risk. If you would invest  46,239  in Ameriprise Financial on September 19, 2024 and sell it today you would earn a total of  7,947  from holding Ameriprise Financial or generate 17.19% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Ameriprise Financial  vs.  Mineralys Therapeutics, Common

 Performance 
       Timeline  
Ameriprise Financial 

Risk-Adjusted Performance

12 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Ameriprise Financial are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Even with relatively abnormal primary indicators, Ameriprise Financial reported solid returns over the last few months and may actually be approaching a breakup point.
Mineralys Therapeutics, 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Mineralys Therapeutics, Common are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Mineralys Therapeutics, may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Ameriprise Financial and Mineralys Therapeutics, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Ameriprise Financial and Mineralys Therapeutics,

The main advantage of trading using opposite Ameriprise Financial and Mineralys Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Ameriprise Financial position performs unexpectedly, Mineralys Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mineralys Therapeutics, will offset losses from the drop in Mineralys Therapeutics,'s long position.
The idea behind Ameriprise Financial and Mineralys Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Other Complementary Tools

Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets